TARDBP and amyotrophic lateral sclerosis: Lastly, TDP-43 overexpression leads to TDP-43 splicing gain of function, and not to the TDP-43 loss of function that defines end and possibly mid-stage disease in ALS patients (Irwin et al. 2024).